These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 26243702)

  • 21. Comorbidities in polycystic ovary syndrome: their relationship to insulin resistance.
    Bethea SW; Nestler JE
    Panminerva Med; 2008 Dec; 50(4):295-304. PubMed ID: 19078870
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polycystic ovary syndrome. Revised diagnostic criteria and long-term health consequences.
    Kousta E; Tolis G; Franks S
    Hormones (Athens); 2005; 4(3):133-47. PubMed ID: 16613823
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polycystic ovary syndrome: a biopsychosocial understanding in young women to improve knowledge and treatment options.
    Moran L; Gibson-Helm M; Teede H; Deeks A
    J Psychosom Obstet Gynaecol; 2010 Mar; 31(1):24-31. PubMed ID: 20050767
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Maternal obesity and associated reproductive consequences.
    Brown K; Apuzzio J; Weiss G
    Womens Health (Lond); 2010 Mar; 6(2):197-203. PubMed ID: 20187726
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gestational diabetes after infertility treatment for polycystic ovarian syndrome.
    Jammah AA; Somal KK; Power SG; McManus RM
    Saudi Med J; 2009 Apr; 30(4):575-6. PubMed ID: 19370293
    [No Abstract]   [Full Text] [Related]  

  • 26. Comprehensive Evaluation of Type 2 Diabetes and Cardiovascular Disease Risk Profiles in Reproductive-Age Women with Polycystic Ovary Syndrome: A Large Canadian Cohort.
    Kazemi M; Pierson RA; Lujan ME; Chilibeck PD; McBreairty LE; Gordon JJ; Serrao SB; Zello GA; Chizen DR
    J Obstet Gynaecol Can; 2019 Oct; 41(10):1453-1460. PubMed ID: 30712903
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fertility in polycystic ovary syndrome.
    Patel SM; Nestler JE
    Endocrinol Metab Clin North Am; 2006 Mar; 35(1):137-55, vii. PubMed ID: 16310646
    [No Abstract]   [Full Text] [Related]  

  • 28. Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women.
    Escobar-Morreale HF; Villuendas G; Botella-Carretero JI; Sancho J; San Millán JL
    Diabetologia; 2003 May; 46(5):625-33. PubMed ID: 12739017
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elevation of isoprostanes in polycystic ovary syndrome and its relationship with cardiovascular risk factors.
    Calzada M; López N; Noguera JA; Mendiola J; Torres AM
    J Endocrinol Invest; 2019 Jan; 42(1):75-83. PubMed ID: 29687417
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus.
    Ovalle F; Azziz R
    Fertil Steril; 2002 Jun; 77(6):1095-105. PubMed ID: 12057712
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The cardiometabolic effect of current management of polycystic ovary syndrome: strategies of prevention and treatment.
    Baldani DP; Skrgatic L; Ougouag R; Kasum M
    Gynecol Endocrinol; 2018 Feb; 34(2):87-91. PubMed ID: 28944709
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polycystic ovaries and associated metabolic abnormalities in Indian subcontinent Asian women.
    Rodin DA; Bano G; Bland JM; Taylor K; Nussey SS
    Clin Endocrinol (Oxf); 1998 Jul; 49(1):91-9. PubMed ID: 9797852
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gestational diabetes mellitus - A metabolic and reproductive disorder.
    Choudhury AA; Devi Rajeswari V
    Biomed Pharmacother; 2021 Nov; 143():112183. PubMed ID: 34560536
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolic and cardiovascular consequences of polycystic ovary syndrome.
    Orio F; Vuolo L; Palomba S; Lombardi G; Colao A
    Minerva Ginecol; 2008 Feb; 60(1):39-51. PubMed ID: 18277351
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polycystic ovary syndrome and the postmenopausal woman.
    Ireland K; Child T
    J Br Menopause Soc; 2006 Dec; 12(4):143-8. PubMed ID: 17178014
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current perspectives of insulin resistance and polycystic ovary syndrome.
    Pauli JM; Raja-Khan N; Wu X; Legro RS
    Diabet Med; 2011 Dec; 28(12):1445-54. PubMed ID: 21950959
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endocrine abnormalities. Foreword.
    Schapiro NA
    Curr Probl Pediatr Adolesc Health Care; 2013; 43(5):103. PubMed ID: 23582591
    [No Abstract]   [Full Text] [Related]  

  • 38. Insulin resistance in patients with polycystic ovary syndrome.
    Schröder AK; Tauchert S; Ortmann O; Diedrich K; Weiss JM
    Ann Med; 2004; 36(6):426-39. PubMed ID: 15513294
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Polycystic Ovarian Syndrome: Long-Term Health Consequences.
    Zore T; Joshi NV; Lizneva D; Azziz R
    Semin Reprod Med; 2017 May; 35(3):271-281. PubMed ID: 28658711
    [No Abstract]   [Full Text] [Related]  

  • 40. Polycystic ovary syndrome: cardiovascular risk factors according to specific phenotypes.
    Aziz M; Sidelmann JJ; Faber J; Wissing ML; Naver KV; Mikkelsen AL; Nilas L; Skouby SO
    Acta Obstet Gynecol Scand; 2015 Oct; 94(10):1082-9. PubMed ID: 26123797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.